title: The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
abstract: Ceftazidime is the only anti-pseudomonal beta-lactam that has been reported to be administered by extended infusion in pediatric cystic fibrosis (CF) patients. A small pediatric pharmacokinetic/pharmacodynamic study has been published regarding the use of intermittent extended infusion doripenem in the treatment of an acute pulmonary exacerbation (APE) in pediatric CF patients; however, clinical use of intermittent extended infusion doripenem in pediatric CF patients has not been previously reported. We present three cases administering intermittent extended infusion doripenem in pediatric CF patients for the treatment of an APE in the case of replacing meropenem due to shortage. The delivery of beta-lactam antibiotics via intermittent extended infusion should be considered in order to optimize the pharmacodynamics of beta-lactams in the treatment of an APE.
authors: Pharmacy, Intermountain Primary Children's Medical Center, Salt Lake City, Utah; Intermountain Cystic Fibrosis Pediatric Center, Salt Lake City, Utah.
authors: Jeffery T
authors: JT
authors: Zobell
authors: Andrea L
authors: AL
authors: Kemper
authors: David C
authors: DC
authors: Young
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000600:supply & distribution / Q000627:therapeutic use*; D019121:Burkholderia Infections / Q000150:complications / Q000188:drug therapy*; D057508:Burkholderia cenocepacia / Q000302:isolation & purification; D015780:Carbapenems / Q000627:therapeutic use*; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D018450:Disease Progression; D000077726:Doripenem; D004359:Drug Therapy, Combination; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D000077731:Meropenem; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D044223:Pseudomonas stutzeri / Q000302:isolation & purification; D012244:Rhodospirillaceae / Q000302:isolation & purification; D013845:Thienamycins / Q000600:supply & distribution; D014031:Tobramycin / Q000627:therapeutic use; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000077726:Doripenem; D000077731:Meropenem; D014031:Tobramycin
keywords: Burkholderia cenocepacia; Inquilinus limosus; Pseudomonas aeruginosa; antibiotics; beta-lactams